Poole Aleksandra Jovanovic, Li Ying, Kim Yoon, Lin Suh-Chin J, Lee Wen-Hwa, Lee Eva Y-H P
Department of Biological Chemistry, University of California, Irvine, CA 92697-4037, USA.
Science. 2006 Dec 1;314(5804):1467-70. doi: 10.1126/science.1130471.
Women with mutations in the breast cancer susceptibility gene BRCA1 are predisposed to breast and ovarian cancers. Why the BRCA1 protein suppresses tumor development specifically in ovarian hormone-sensitive tissues remains unclear. We demonstrate that mammary glands of nulliparous Brca1/p53-deficient mice accumulate lateral branches and undergo extensive alveologenesis, a phenotype that occurs only during pregnancy in wild-type mice. Progesterone receptors, but not estrogen receptors, are overexpressed in the mutant mammary epithelial cells because of a defect in their degradation by the proteasome pathway. Treatment of Brca1/p53-deficient mice with the progesterone antagonist mifepristone (RU 486) prevented mammary tumorigenesis. These findings reveal a tissue-specific function for the BRCA1 protein and raise the possibility that antiprogesterone treatment may be useful for breast cancer prevention in individuals with BRCA1 mutations.
乳腺癌易感基因BRCA1发生突变的女性易患乳腺癌和卵巢癌。BRCA1蛋白为何特别在对卵巢激素敏感的组织中抑制肿瘤发展尚不清楚。我们证明,未生育的Brca1/p53基因缺陷小鼠的乳腺积累侧支并经历广泛的腺泡形成,这种表型仅在野生型小鼠怀孕时出现。由于蛋白酶体途径对其降解存在缺陷,突变的乳腺上皮细胞中孕激素受体而非雌激素受体过度表达。用孕激素拮抗剂米非司酮(RU 486)治疗Brca1/p53基因缺陷小鼠可预防乳腺肿瘤发生。这些发现揭示了BRCA1蛋白的组织特异性功能,并增加了抗孕激素治疗可能对BRCA1突变个体预防乳腺癌有用的可能性。
Science. 2006-12-1
Curr Opin Obstet Gynecol. 2008-2
Biochem Biophys Res Commun. 2012-11-15
Int J Mol Sci. 2025-3-25
Adv Exp Med Biol. 2025
Ann Oncol. 2025-2
Obstet Gynecol Sci. 2024-7
bioRxiv. 2024-8-19
Dis Model Mech. 2023-11-1